Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

1.

OMI and Ground-Based In-Situ Tropospheric Nitrogen Dioxide Observations over Several Important European Cities during 2005-2014.

Paraschiv S, Constantin DE, Paraschiv SL, Voiculescu M.

Int J Environ Res Public Health. 2017 Nov 20;14(11). pii: E1415. doi: 10.3390/ijerph14111415.

2.
3.

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.

Roger SD, Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Cronin M, Meier Y, Larroque S, Macdougall IC; FIND-CKD Study Investigators.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1530-1539. doi: 10.1093/ndt/gfw264.

PMID:
28339831
4.

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Roger SD; FIND-CKD Study investigators.

BMC Nephrol. 2017 Jan 17;18(1):24. doi: 10.1186/s12882-017-0444-6.

5.

Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C.

Sultana C, Oprişan G, Teleman MD, Dinu S; HepGen 88/2012 Project Team, Oprea C, Voiculescu M, Ruta S.

World J Gastroenterol. 2016 Oct 7;22(37):8406-8413.

6.

Importance of arterial stiffness in predicting cardiovascular events.

Ecobici M, Voiculescu M.

Rom J Intern Med. 2017 Mar 1;55(1):8-13. doi: 10.1515/rjim-2016-0043.

PMID:
27490029
7.

Non-Alcoholic Steatohepatitis: Clinical and Translational Research.

Neuman MG, Voiculescu M, Nanau RM, Maor Y, Melzer E, Cohen LB, Opris M, Malnick S.

J Pharm Pharm Sci. 2016;19(1):8-24. doi: 10.18433/J3F61F. Review.

8.

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group.

Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11.

9.

How Far we are towards Eradication of HBV Infection.

Voiculescu M.

J Gastrointestin Liver Dis. 2015 Dec;24(4):473-9. doi: 10.15403/jgld.2014.1121.244.hbv. Review.

10.

The effect of caffeine on cerebral asymmetry in rats.

Voiculescu M, Segarceanu A, Negutu M, Ghita I, Fulga I, Coman OA.

J Med Life. 2015 Oct-Dec;8(4):476-82.

11.

Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies.

Zilişteanu DS, Atasie T, Voiculescu M.

Rom J Intern Med. 2015 Apr-Jun;53(2):161-9.

PMID:
26402986
12.

Current therapies in hepatorenal syndrome.

Achim C, Zgură A, Zgură D, Voiculescu M.

Rom J Intern Med. 2014 Oct-Dec;52(4):201-15. Review.

PMID:
25726622
13.

Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

Pais R, Rusu E, Zilisteanu D, Circiumaru A, Micu L, Voiculescu M, Poynard T, Ratziu V.

Eur J Intern Med. 2015 Jan;26(1):30-6. doi: 10.1016/j.ejim.2014.12.001. Epub 2014 Dec 29.

PMID:
25553983
14.

Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma.

Voiculescu M, Nanau RM, Neuman MG.

J Gastrointestin Liver Dis. 2014 Dec;23(4):425-9. doi: 10.15403/jgld.2014.1121.234.bna. Review.

15.

Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).

Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL; ARES Study Group.

Hepatology. 2015 May;61(5):1512-22. doi: 10.1002/hep.27586. Epub 2015 Feb 27.

PMID:
25348661
16.

Alcoholic and non-alcoholic steatohepatitis.

Neuman MG, French SW, French BA, Seitz HK, Cohen LB, Mueller S, Osna NA, Kharbanda KK, Seth D, Bautista A, Thompson KJ, McKillop IH, Kirpich IA, McClain CJ, Bataller R, Nanau RM, Voiculescu M, Opris M, Shen H, Tillman B, Li J, Liu H, Thomes PG, Ganesan M, Malnick S.

Exp Mol Pathol. 2014 Dec;97(3):492-510. doi: 10.1016/j.yexmp.2014.09.005. Epub 2014 Sep 11. Review.

17.

Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.

Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K.

Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. doi: 10.1016/j.cgh.2014.01.040. Epub 2014 Feb 12.

PMID:
24530600
18.

Satellite observations of NO2 trend over Romania.

Constantin DE, Voiculescu M, Georgescu L.

ScientificWorldJournal. 2013 Dec 25;2013:261634. doi: 10.1155/2013/261634. eCollection 2013.

19.

Molecular and pharmacodynamic interactions between caffeine and dopaminergic system.

Voiculescu M, Ghiță I, Segărceanu A, Fulga I, Coman O.

J Med Life. 2014;7 Spec No. 4:30-8. Review.

20.

Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries.

Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-Klozinska B, Simon K, Suceveanu AI, Wiese M, Zeuzem S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zarski JP; AI463-121 European Longitudinal Chronic Hepatitis B Study Group.

J Viral Hepat. 2014;21(9):662-70. doi: 10.1111/jvh.12202. Epub 2013 Dec 15.

PMID:
24329883

Supplemental Content

Loading ...
Support Center